- Home
- SPRB
as 07-26-2024 4:00pm EST
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 22.5M | IPO Year: | 2020 |
| Target Price: | $2.50 | AVG Volume (30 days): | 437.1K |
| Analyst Decision: | Hold | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.50 - $5.95 | Next Earning Date: | 08-12-2024 |
| Revenue: | $10,127,000 | Revenue Growth: | 415.63% |
| Revenue Growth (this year): | -36.65% | Revenue Growth (next year): | -59.30% |
Stock Insider Trading Activity of Spruce Biosciences Inc. (SPRB)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Novo Holdings A/S | SPRB | 10% Owner | Mar 21 '24 | Sell | $0.75 | 465,021 | $350,951.35 | 2,550,000 | SEC Form 4 |
| Novo Holdings A/S | SPRB | 10% Owner | Mar 18 '24 | Sell | $0.77 | 842,020 | $647,008.17 | 3,968,000 | SEC Form 4 |
| Novo Holdings A/S | SPRB | 10% Owner | Mar 18 '24 | Sell | $0.76 | 593,000 | $447,715.00 | 3,375,000 | SEC Form 4 |
| Novo Holdings A/S | SPRB | 10% Owner | Mar 18 '24 | Sell | $0.73 | 359,979 | $264,080.59 | 3,015,021 | SEC Form 4 |
| Novo Holdings A/S | SPRB | 10% Owner | Mar 14 '24 | Sell | $0.89 | 1,912,316 | $1,698,901.53 | 4,810,020 | SEC Form 4 |
Latest Spruce Biosciences Inc. News
SPRB Breaking Stock News: Dive into SPRB Ticker-Specific Updates for Smart Investing
Clinical Trials Arena
a month ago
Pipeline Moves: Approval prospects for BioTissue’s diabetic foot ulcer drug up after Phase III completion
PR Newswire
2 months ago
NexTech Solutions Has Agreed to Acquire Rome Research Corporation to Expand Service Offerings and Enhance Mission Support Capabilities
Business Wire
2 months ago
Form 8.3 - Darktrace plc
Business Wire
2 months ago
Form 8.3 - International Distribution Services plc
Reuters
2 months ago
US Supreme Court rejects Kroger challenge to Grubhub trademark win
Investor's Business Daily
2 months ago
Dow Jones Falls As AMD Slides On Downgrade; Nvidia Stock Split Takes Effect
Business Wire
2 months ago
GoldATM Supports Growing Consumer Demand for Gold Purchase with New ATMs in North Carolina
GlobeNewswire
2 months ago
Middlefield Canadian Income PCC: Net Asset Value(s)
Compare SPRB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SPRB Spruce Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.